Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Homocysteine recently gained access to the category of risk factor for the development of atherosclerotic cardiovascular disease in the general population. Chronic renal failure patients, even before being introduced to dialysis therapy have almost universal elevation of serum homocysteine; when on dialysis their mortality is above 50% related to cardiovascular disease that we might now speculate, with a contribution of potentially toxic levels of the aminoacid homocysteine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade Estadual de Londrina
• Treatments: Folic Acid; Vitamin B Complex

Criteria

Inclusion Criteria:

• Patients stable on hemodialysis for 4 months or more

• Eighteen years of age or older

Exclusion Criteria:

• Potential kidney transplant from a living donor in the near future

• Severe cardiovascular disease

• Cancer and active inflammation